Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC

December 17th 2024

The FDA has issued a CRL to the BLA seeking approval of subcutaneous amivantamab for use in patients with EGFR-mutated non–small cell lung cancer.

NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers

December 17th 2024

NRG1 fusion positivity has gained interest as a treatment target in lung and pancreatic cancer, leading to the FDA approval of zenocutuzumab in December 2024.

Dr Halmos on Novel Targets for Drug Development in SCLC

December 16th 2024

Balazs Halmos, MD, discusses novel targets for drug development in small cell lung cancer.

Dr Halmos on the Challenges of Diagnosing SCLC

December 16th 2024

Balazs Halmos, MD, discusses challenges associated with the diagnosis and treatment of patients with small cell lung cancer.

Perioperative Pembrolizumab Plus Chemo Wins Approval in China for Resectable Stage II/III NSCLC

December 16th 2024

China’s NMPA has approved perioperative pembrolizumab plus chemotherapy for select patients with resectable non–small cell lung cancer.

The OncFive: Top Oncology Articles for the Week of 12/8

December 14th 2024

Fixed-duration acalabrutinib combination improves PFS in CLL, imlunestrant ± abemaciclib boosts PFS in ESR1-mutated ER+ breast cancer, and more.

Biomarker-Guided Treatment Approaches Transform Lung and GI Cancer Management

December 13th 2024

Experts across the fields of lung and GI cancer share key information and insights from 2 recent OncLive biomarker consortiums.

China’s NMPA Grants Breakthrough Therapy Designation to Savolitinib Plus Osimertinib in EGFR+ NSCLC

December 12th 2024

Savolitinib plus osimertinib received breakthrough therapy designation in China for pretreated, locally advanced or metastatic EGFR-positive NSCLC with MET amplification.

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

December 12th 2024

Drs Park and Liu discuss the use of amivantamab plus lazertinib in EGFR-mutated non–small cell lung cancer.

FDA Grants Breakthrough Therapy Designation to Dato-DXd for Previously Treated EGFR+ Advanced NSCLC

December 9th 2024

The FDA granted breakthrough therapy designation to Dato-DXd for previously treated EGFR-mutated advanced non–small cell lung cancer.

Immunotherapy Reshapes Perioperative Strategies for Early NSCLC Without Driver Mutations

December 5th 2024

Roy S. Herbst, MD, explores evolving chemoimmunotherapy strategies for early-stage NSCLC that does not harbor actionable mutations.

Dr Senan on the FDA Approval of Durvalumab for LS-SCLC

December 4th 2024

Suresh Senan, MRCP, FRCR, PhD, discusses the significance of the FDA approval of durvalumab for patients with limited-stage small cell lung cancer.

FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer

December 4th 2024

The FDA has approved durvalumab for adults with limited-stage small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

Dr Schram on the FDA Approval of Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer

December 4th 2024

Alison Schram, MD, discusses the FDA approval of zenocutuzumab in non–small cell lung cancer and pancreatic cancer harboring NRG1 fusions.

FDA Grants Accelerated Approval to Zenocutuzumab for NRG1+ NSCLC and Pancreatic Adenocarcinoma

December 4th 2024

The FDA granted accelerated approval to zenocutuzumab for select patients with NSCLC and pancreatic adenocarcinoma with NRG1 fusions.

FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan for EGFR+ NSCLC

December 3rd 2024

Sacituzumab tirumotecan has received breakthrough therapy designation from the FDA for use in select patients with EGFR+ non–small cell lung cancer.

OncLive’s November Roundup of Key FDA Approvals in Oncology

December 3rd 2024

Here is your snapshot of all treatment options that the FDA cleared in November 2024 spanning tumor types.

The OncFive: Top Oncology Articles for the Week of 11/24

November 30th 2024

Belantamab mafodotin is under FDA review in multiple myeloma, and Suneel Kamath, MD, highlights pancreatic cancer awareness month.

Osimertinib as Consolidation Therapy for Unresectable Locally Advanced Disease Is Most Impactful Addition to 2024 NSCLC NCCN Guidelines

November 29th 2024

Jonathan Wesley Riess, MD, MS, and Megan E. Daly, MD, provide radiation and medical oncology perspectives on NCCN guideline updates in lung cancer.

Tiragolumab Plus Atezolizumab Fails to Meet OS End Point in PD-L1–High NSCLC

November 26th 2024

The addition of tiragolumab to atezolizumab did not significantly improve OS vs atezolizumab alone in PD-L1–high non–small cell lung cancer.